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Background: The mouse is an organism that is widely used as a mammalian model for studying human
physiology or disease, and the development of immunodeficient mice has provided a valuable tool for basic
and applied human disease research. Following the development of large-scale mouse knockout programs
and genome-editing tools, it has become increasingly efficient to generate genetically modified mouse strains
with immunodeficiency. However, due to the lack of a standardized system for evaluating the immuno-capacity that
prevents tumor progression in mice, an objective choice of the appropriate immunodeficient mouse strains to be used
for tumor engrafting experiments is difficult.
Methods: In this study, we developed a tumor engraftment index (TEI) to quantify the immunodeficiency response
to hematologic malignant cells and solid tumor cells of six immunodeficient mouse strains and C57BL/6 wild-type
mouse (WT).
Results: Mice with a more severely impaired immune system attained a higher TEI score. We then validated that
the NOD-scid-IL2Rg−/− (NSI) mice, which had the highest TEI score, were more suitable for xenograft and
allograft experiments using multiple functional assays.
Conclusions: The TEI score was effectively able to reflect the immunodeficiency of a mouse strain.
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Research on human diseases has relied on experiments
using immunodeficient mouse models [1]. The deriva-
tions of nude and severe combined immunodeficiency
(scid) mice, which are widely used for xenotransplant-
ation, were milestones in the development of immuno-
deficient mice. However, although nude mice lacked T
cells, they harbored B cells and natural killer (NK) cells
and did not allow lasting human cell reconstitution [2].
The limitations that impeded human cell engraftment in
scid and recombination-activating 2 deficient (Rag2−/−)
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creativecommons.org/publicdomain/zero/1.0/high levels of host NK cells [3, 4]. The development of
NOD.Cg-Prkdcscid (NOD-scid) mice with lower levels of
NK cells and additional innate immune defects allowed
higher levels of human cell engraftment, but the mice
were still not ideal [5]. A major breakthrough in the
generation of humanized mice was the development
of immunodeficient IL2Rg−/− mice, such as the NOD/
ShiLtSz-scid/IL2Rγnull (NSG) and NOD/ShiJic-scid/IL2Rγnull
(NOG) strains. These mice withstood greatly increased en-
graftments of human tissues (hematopoietic stem cells
(HSCs) and peripheral blood mononuclear cells (PBMCs))
than all previously developed immunodeficient humanized
mouse models [6, 7]. Cancer cells and the host immune
system constantly interact with one another in the tumor
microenvironment [8, 9]. Clinical data have demonstrated
that immunodeficient individuals are susceptible to a
dramatic increase in tumor incidence. For example, thedistributed under the terms of the Creative Commons Attribution License
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patients compared with the general population [10].
Consistently with immunodeficient patients, STAT-1−/−
and RAG−/− mice showed a significantly increased in-
cidence of observable cancers compared with their non-
immunodeficient counterparts [11, 12]. Thus, a greater
severity of immune deficiency led to a greater degree of
tumor growth in immunodeficient mice.
Following the development of large-scale mouse knock-
out programs [13] and genome-editing tools, such as zinc-
finger nuclease (ZFN) [14], transcription activator-like
effector nuclease (TALEN) [15–17] and the type II clus-
tered, regularly interspaced, short palindromic repeat
(CRISPR)-associated (Cas) system [18–20], it has become
increasingly efficient to generate genetically modified
mouse strains that cannot easily be generated using
traditional hybridization [21]. However, because no stan-
dardized system for evaluating immunodeficiency in mice
currently exists, an objective comparison of the immuno-
deficiency of various immunodeficient mouse strains is
difficult.
In this study, we developed a tumor engraftment index
(TEI), using six representative immunodeficient mouse
models, combining the hematopoietic and solid tumor
model and the allograft and xenograft models, and created
a statistical formula for a simple and accurate method to
quantify the immunodeficiency of mouse strains. We
showed that the NOD-scid-IL2Rg−/− (NSI) mice had the
highest TEI scores in both the xenograft and allograft
tests. Moreover, we validated the TEI scoring results using
human-derived HSC, human bone marrow/liver/thymus
(BLT), single primary B cell acute lymphoblastic leukemia
(B-ALL) cell transplantation models, and primary tumors
from lung cancer patients.
Results
Assessing the ability to prevent the engraftment of
hematological tumors
Immunodeficiency is positively correlated with the cap-
acity for tumor engraftment [22, 23]. We chose C57BL/6
wild-type (WT) and six well-characterized immunodefi-
cient mouse strains, namely nude [2], scid [3], NOD-scid
[5], B6.129S4-IL2Rg−/− (IL2Rg−/−) [24], Rag2−/− [4],
and NOD-scid-IL2Rg−/− [5, 7] mice, to assess immuno-
deficiency. Because the NSG and NOG strains are not
commercially available in China, we generated the
NOD-scid-IL2Rg−/− (NSI) strain, which did not harbor
T, B, or NK cells, by TALEN-mediated gene targeting in
the NOD background [25].
For an accurate quantification, we first evaluated the
immunodeficiency of a mouse strain by measuring its
ability to prevent hematologic tumor engraftment. We
injected K562-GFP cells [26], a human chronic myeloid
leukemia cell line with Philadelphia chromosome, whichconstitutively expressed green fluorescent protein (GFP)
(Additional file 1: Figure S1) into the seven mouse strains
without any preconditioning, and assessed the percentages
of tumor cells in certain tissues of the recipients. Three
groups of mice (five mice per group) were assayed with
a high number (1 × 106, H), medium number (1 × 105,
M), and low number (1 × 104, L) of grafts, respectively
(Additional file 2: Figure S2). The survival curves of each
group of the seven mouse strains are shown in Fig. 1. The
median survival time was 19 days in NSI mice, 21 days in
NOD-scid mice, 23 days in scid mice, and 45 days in
IL2Rg−/− mice when 1 × 106 K562-GFP cells were injected
(Fig. 1a). No K562 cells were detected in WT mice after
transplantation (Fig. 1a). After the injection of 1 × 105
K562-GFP cells, successful reconstitution of leukemia was
observed in NSI (medium survival time 27 days) and
NOD-scid (medium survival time 48 days) mice (Fig. 1b),
but not in IL2Rg−/−, scid, Rag2−/−, nude, or WT mice.
The injection of 1 × 104 K562-GFP cells reconstituted
leukemia in the NSI mice, whereas leukemia cells were
under detectable in NOD-scid, IL2Rg−/−, scid, Rag2−/−,
nude, or WT mice (Fig. 1c). Because K562 cells were not
detected in the bone marrow (BM) or spleen (SP) of the
seven strains tested, we then measured the percentages of
K562 cells in the peripheral blood (PB) of each mouse and
found that the engraftment efficiencies were highest in
the NSI mice, followed by the NOD-scid, IL2Rg−/−, scid,
Rag2−/−, and nude mice, in that order (Fig. 1d).
Similarly, we measured the immunodeficiency of the
seven strains for hematologic allografts by injecting
RMA-GFP cells [27], which continuously expressed GFP
(Additional file 1: Figure S1 and Additional file 2: Figure S2).
The lifespan of each strain after tumor transplantation
increased in the sequential order of NSI, IL2Rg−/−, NOD-
scid, scid, Rag2−/−, nude, and WTafter 1 × 106 RMA-GFP
cells were injected (Fig. 2a). The injection of 1 × 105
RMA-GFP cells did not reconstitute tumors in WT
mice (Fig. 2b). After the injection of 1 × 104 RMA-GFP
cells, successful engraftments were detected in only NSI,
IL2Rg−/−, and NOD-scid mice (Fig. 2c). We measured the
percentages of RMA-GFP in the PB (Fig. 2d), SP (Fig. 2e),
and BM (Fig. 2f) of each mouse.
Assessing the ability to prevent the engraftment of solid
tumor
To evaluate the feasibility of the seven mouse strains for
solid tumor xenografts, we measured the immunodefi-
ciency of a mouse strain by testing its ability to prevent
solid tumor engraftment. We subcutaneously injected the
six immunodeficient mouse strains and WT mice with
A549 cells (for xenografts), a human adenocarcinoma al-
veolar basal epithelial cell line [28], or B16F10 cells (for al-
lografts), which are a murine skin melanoma [29], to assess
the tumor mass. Three groups of mice (five mice per
Fig. 1 Assessing the ability to withstand a leukemic xenograft in immunodeficient mice. Kaplan-Meyer survival analysis of NSI, IL2Rg−/−, NOD-scid,
scid, Rag2−/−, nude, and WT mice injected with a high number (1 × 106, a), medium number (1 × 105, b), and low number (1 × 104, c) of K562-GFP
cells. d The percentages of K562-GFP cells in the peripheral blood (PB) of each mouse in the same experiments in (a). Bars represent the mean
percentages of human K562-GFP cells in the PB of mice from each strain (n = 5)
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medium number (1 × 105, M), and low number (1 × 104, L)
of grafts, respectively (Additional file 2: Figure S2). Twenty
days (for allografts) or 30 days (for xenografts) after
transplantation, the engraftment efficiencies of the tumor
cells were determined by measuring the mass of the tumor
under the skin.
Notably, we found that 1 × 104 A549 cells were able to
form tumors in the NSI mice, whereas 1 × 105 A549 cells
were required for successful engraftments in the NOD-
scid, scid, and nude mice (Fig. 3a). However, 1 × 106 A549
cells were needed to induce tumorigenesis in Rag2−/−
and IL2Rg−/− mice. No tumors were observed in WT
mice (Fig. 3a). Similarly, we measured the immunodefi-
ciency of the seven strains for allografts by injecting
B16F10 cells into five mice of each strain (Additional file 2:
Figure S2). Consistent with the A549 xenograft results,
tumors were detected in NSI mice after the injection
of as few as 1 × 104 B16F10 cells (Fig. 3b). The weights
of the tumors increased in the sequential order of WT,
nude, IL2Rg−/−, scid, Rag2−/−, NOD-scid, and NSI
mice after the injection of 1 × 105 or 1 × 106 B16F10
cells (Fig. 3b).Formula to quantify the immunodeficiency of the
immunodeficient mice
The capacities of both hematologic and solid tumor induc-
tion in the seven mouse strains evaluated suggested that
the immunodeficiency was positively correlated with the
capacity for tumor engraftment, which was also supported
by previous studies [22, 23]. To quantify the immunodefi-
ciency of a specific mouse strain, we developed a tumor en-
graftment index (TEI) that is negatively correlated to its
capacity to prevent the development of non-self tumor
cells. For a given time of death, TEI is proportional to the
engraftment efficiency. However, for a given engraftment
efficiency, TEI is inversely proportional to the time of death
of the mice injected with tumor. For example, the TEI of
WT or normal mice having a healthy immune system was
zero; the TEI of mice with a severely impaired immune sys-
tem was substantially higher. Therefore, we propose that
the TEI of an individual mouse can be calculated by divid-
ing its tumor engraftment by its lifespan after injection with
the tumor cells. The quantification of tumor engraftments
varies between hematologic tumors and solid tumors.
For the hematologic tumor engraftment index,
Istrain−hematologic tumor−n ¼ GiDi where “strain” is the name of
Fig. 2 Assessing the ability to withstand a leukemic allograft in immunodeficient mice. Kaplan-Meyer survival analysis of NSI, IL2Rg−/−, NOD-scid,
scid, Rag2−/−, nude, and WT mice injected with a high number (1 × 106, a), medium number (1 × 105, b), and low number (1 × 104, c) of RMA-GFP
cells. c Level of RMA-GFP cells in peripheral blood (PB, d), spleen (SP, e), and bone marrow (BM, f) of each mouse with reference to (a). Bars represent
the mean percentages of human K562-GFP cells in the PB, SP, and BM of mice from each strain (n = 5)
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name of the tumor cells; n denotes the number of individ-
uals; “Gi” is the sum of the percentages of tumor cells in
the peripheral blood (GPB), bone marrow (GBM), and
spleen (GSP) of an individual mouse when the mouse is
morbid or killed; and “Di” is the lifespan of the individual
mouse after injection of the tumor cells.
For the solid tumor engraftment index, Istrain−solid tumor−n ¼ WiD
where “strain” is the name of the immunodeficient mice,
“solid tumor” is the type of tumor cells for transplantation,
n denotes the number of individuals, “Wi” is the weight ofthe graft in the mouse when the mouse is morbid or
killed, and D is the survival time of the mouse after injec-
tion of the tumor.
The final score of the TEI is the average of In of
hematologic and solid tumors:
Istrain−allograft−n ¼ Istrain−RMA−n þ Istrain−B16F10−nð Þ=2
Istrain−xenograft−n ¼ Istrain−k562−n þ Istrain−A549−nð Þ=2
To improve the convenience of calculation of TEI
scores, we designed the website (http://www.nsitei.com)
Fig. 3 Assessing the ability to withstand a solid tumor in immunodeficient mice. The weight of the solid xenografts (a) and allografts (b) in NSI,
IL2Rg−/−, NOD-scid, scid, Rag2−/−, nude, and WT mice transplanted with a high number (1 × 106), medium number (1 × 105), and low number
(1 × 104) of A549 or B16F10. Bars represent the mean weight of grafts from mice of each strain (n = 5)
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TEI equation, we calculated the TEI scores for each
strain (Additional file 3: Table S1 and Additional file 4:
Table S2) and found that NSI mice had the highest TEI
scores in both the xenograft and allograft tests, followed
by scid, nude, and WT mice. Interestingly, the allograft
TEI scores of IL2Rg−/− were higher than those of NOD-
scid and scid mice (Fig. 4a), whereas IL2Rg−/− had lower
TEI scores than NOD-scid and scid mice in the xeno-
graft tests (Fig. 4b). The recent observations of greater
leukemogenic engraftment in NSG mice than in NOD-
scid mice [22], and of the greater susceptibility to tumor
formation of NOG mice than nude and scid mice [23],
indicated that the TEI scoring system provides an effi-
cient method to assess the tumor engraftment efficiency
of immunodeficient mice.
Hematopoietic functional assay in NSI mice
We then used three types of functional assay to validate
whether NSI mice were more suitable for xenograft than
NOD-scid mice, as suggested by the TEI results. First,
we compared the human hematopoietic engraftmentcapacities of the NSI mice and NOD-scid mice by
engrafting the sub-lethally irradiated mice with 1 × 104
and 1 × 105 of human umbilical cord blood CD34+ cells,
respectively. Twelve weeks after the transplantations, the
percentages of human CD45+ cells in the PB, SP, and BM
of the NSI mice were significantly higher than those of the
NOD-scid mice (Fig. 5a). Furthermore, the injected human
CD34+ cells differentiated into multiple hematopoietic lin-
eages, including B cells, T cells, and myeloid cells (Fig. 5b).
Second, we examined whether human hematopoietic
progenitors were able to reconstitute a functional immune
system in NSI mice. We established a humanized BLT
mouse model by surgically implanting human thymus
and liver fragments into kidney capsules and injecting
donor-matched human hematopoietic stem/progenitor
cells (CD34+) intravenously into NSI mice (Additional
file 5: Figure S3). Twelve weeks after transplantation, we
analyzed the immune system in the recipient BLT-NSI
mice. We found human mature CD4+ and CD8+ T cells,
CD19+ immunoglobulin (Ig)M+ mature B cells, CD56+
NK cells, and CD14/33+ monocytes/macrophages in the
BLT-NSI mice (Fig. 5c). More importantly, we detected
Table 1 Equation for calculating TEI scores
TEI score for RMAa
Mouse number H M L TEIH TEIM TEIL TEIRMA Average
of TEIRMAGPB GSP GBM D GPB GSP GBM D GPB GSP GBM D (GPB + GSP + GBM)/D (GPB + GSP + GBM)/D (GiPB + GSP + GBM)/D (TEIH + TEIM + TEIL)/3
1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0
2 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
3 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
4 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
5 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
TEI score for B16F10b
Mouse number H M L TEIH TEIM TEIL TEIB16F10 Average of TEIB16F10
W D W D W D G/D G/D G/D (TEIH + TEIM + TEIL)/3
1 0 1 0 1 0 1 0 0 0 0 0
2 0 1 0 1 0 1 0 0 0 0
3 0 1 0 1 0 1 0 0 0 0
4 0 1 0 1 0 1 0 0 0 0
5 0 1 0 1 0 1 0 0 0 0
TEIallograft 0
TEI score for K562c
Mouse number H M L TEIH TEIM TEIL TEIK562 Average
of TEIK562GPB GSP GBM D GPB GSP GBM D GPB GSP GBM D (GPB + GSP + GBM)/D (GPB + GSP + GBM)/D (GiPB + GSP + GBM)/D ((TEIH + TEIM + TEIL)/3)
1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0
2 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
3 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
4 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
5 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0
TEI score for A549d
Mouse number H M L TEIH TEIM TEIL TEIA549 Average of TEIA549
W D W D W D G/D G/D G/D (TEIH + TEIM + TEIL)/3
1 0 1 0 1 0 1 0 0 0 0 0
2 0 1 0 1 0 1 0 0 0 0
3 0 1 0 1 0 1 0 0 0 0
4 0 1 0 1 0 1 0 0 0 0
5 0 1 0 1 0 1 0 0 0 0
TEIxenograft 0
aFill the RMA-GFP engraftment efficiency in PB, SP, BM (GPB, GSP, GBM), and survival day (D) transplanted with H, M, and L of cells in table “TEI score for RMA”
bFill the tumor weight of B16F10 (W) and sacrificed day (D = 20) transplanted with H, M, and L of cells in table “TEI score for B16F10”
cFill the K562-GFP engraftment efficiency in PB, SP, and BM (GPB, GSP, GBM), and survival day (D) transplanted with H, M, and L cells in table “TEI score for K562”
dFill the tumor weight of A549 (W) and sacrificed day (D = 30) transplanted with H, M, and L of cells in table “TEI score for A549”
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Fig. 4 Final TEI score. Summary of the final TEI score of NSI, IL2Rg−/−, NOD-scid, scid, Rag2−/−, nude, and WT mice in the allograft (a) and
xenograft (b) assay
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also ovalbumin (OVA)-specific human IgG from the sera
of the mice after they were immunized with OVA peptides
(Fig. 5d). Conversely, we failed to reconstitute functional
human immune systems in the NOD-scid mice using the
same method (data not shown).
Finally, we tested whether a single human primary leukemic
cell was capable of reconstituting leukemia in NSI mice.
Twenty weeks after the transplantation of a single primary
B-ALL cell, human CD45+ B-ALL was reconstituted in
the NSI mice, but not in the NOD-scid mice (Fig. 5e).
Establishment of solid tumor patient-derived xenografts
with NSI mice
We further examined whether NSI mice were suitable for
modeling solid tumor patient-derived xenograft (PDX).
Ten primary non-small cell lung cancer (NSCLC) samples
from different patients were harvested and implanted sub-
cutaneously into NSI mice (Table 2). Six of the 10 samples
were successfully engrafted in NSI mice (Table 2). There-
fore, the successful rate of modeling NSCLC in PDX using
NSI mice was 60 %, which was higher than the 24.5 %
in NOD-scid mice [30, 31] and 35 % in scid mice [32].
Interestingly, we detected murine Ly6g + CD11b + mac-
rophages in the tumors from the NSCLC PDX models
(Additional file 6: Figure S4). The tumors in the NSCLC
PDX models exhibited similar morphology to that of the
patient tissues from which the primary models were de-
rived (Fig. 6). In addition, dissociated tumor cells from pri-
mary lung cancer samples were also able to reconstitute
tumors with similar morphology to that of the patient tu-
mors (Additional file 7: Figure S5).
Discussion
Several strains of immunodeficient mice are available for
basic and translational research, including BALB/c nude
(nude), scid, NOD-scid, IL2Rg−/−, Rag2−/−, and NOD-
scid-IL2Rg−/− mice. However, the choice of an appropri-
ate immunodeficient mouse strain is difficult, because a
standardized system to evaluate the immunodeficiencyof mice is lacking. In this study, we proposed an index, the
TEI, to represent the capacity of a mouse strain to en-
hance or prevent the expansion of foreign cells in vivo.
We then developed a TEI scoring method to quantitatively
assess the growth of tumor cell lines in different immuno-
deficient mouse strains. Multiple functional assays were
used to validate the correlation between the immunodefi-
ciency of a mouse strain and its TEI score. The final TEI
scores of tested immunodeficient strains are helpful to
select appropriate immunodeficient strains for different
experiments. For example, NSI and IL2Rg−/− strains are
more suitable for allograft studies, while NSI and NOD-
scid strains are preferred for establishing xenografts. Thus,
the TEI scoring system was shown to be a practical and
convenient method to quantify the immunodeficiency of a
mouse strain. It is interesting to notice that IL2Rg−/−
mice exhibited the seemingly paradoxical TEI scores in
allograft and xenograft tests. Due to different genetic mu-
tations in NSI, NOD-scid, and IL2Rg−/− strains, develop-
ment and activities of adaptive and innate immunities,
including B cells, T cells, NK cells, and macrophages, are
different among these strains. In addition, NK cells and T
cells use different machinery to recognize tumors in both
allografts and xenografts. Therefore, the different com-
partments of immune systems in these strains and the
genetic background of tumor cells used in allografts and
xenografts may explain the paradoxical TEI scores of
IL2Rg−/− strain in allograft and xenograft tests.
The immune system not only prevents tumor growth
but also attacks other non-self entities, such as viruses,
fungi, and bacteria [33]. However, immune system re-
sponds to various bacterial, viral, fungal in association
with toll-like receptors and much unknown innate re-
ceptors [33, 34] Thus, the TEI scoring method that only
uses cancer cells for an evaluation cannot assess the im-
munodeficiency of a mouse strain comprehensively. In
addition, it is not practical for an ordinary laboratory to
use viruses or bacteria to measure the immunodeficiency
of certain mouse strains, because most of the immuno-
deficient strains are maintained in specific pathogen-free
Fig. 5 (See legend on next page.)
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Fig. 5 Hematopoietic functional assays of NSI mice. a Summary of percentages of human CD45+ cells in the PB, BM, and SP of NSI (red plot) and
NOD-scid (blue plot) mice 20 weeks after injection with 1 × 104 or 1 × 105 purified human CD34+. Bars represent the mean percentages of human
CD45+ cells in the PB, BM, and SP of mice from each group (n = 4 or 5 per group). *P ≤ 0.05 for bar 1 versus bar 2, bar 3 versus bar 4, bar 5 versus
bar 6, bar 7 versus bar 8, and bar 11 versus bar 12; **P ≤ 0.01 for bar 9 versus bar 10. b Representative FACS analysis of percentages of multiple
hematopoietic lineages in NSI as described in (a). c Representative fluorescence-activated cell sorting (FACS) analysis of percentages of multiple
hematopoietic lineages in NSI transplanted with human cord blood CD34+/liver/thymus. d The level of human IgG (left) and OVA-specific IgG
(right) in serum of NSI mice transplanted with human cord blood CD34+/liver/thymus. Open bars represent NSI mice that received human cord
blood CD34+/liver/thymus (n = 3). Data are represented as the mean ± standard error of the mean. **P ≤ 0.01 for bar 3 versus bar 4 and bar 7
versus bar 8. e Representative FACS analysis of percentages of human CD45+ cells in NSI (right) and Nod-scid (left) transplanted with a
single primary B-ALL cell
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method is more suitable for oncologists than microbiolo-
gists. To evaluate immunodeficiency more comprehensively
and accurately, more parameters need to be incorporated
into the TEI scoring system, including the ability to defend
against bacterial or viral infections.
Conclusions
Due to its simplicity and accuracy, the TEI can be used
widely to help researchers to decide which strain is most
suitable for their xenograft experiments. In addition, the
TEI scoring system may be used to evaluate at least par-
tially the immunodeficiency of genetically modified mice
and other species in oncologic studies in the future.
Material and methods
Mice
Animal experiments were performed in the Laboratory
Animal Center of the Guangzhou Institutes of Biomedicine
and Health (GIBH), and all animal procedures were ap-
proved by the Animal Welfare and Ethical Committee of
GIBH (the ethical process number: N2014050). IL2Rg−/−
mice were purchased from Jackson Laboratories. NOD-
scid, scid, nude, and WT mice were purchased from
Vital River Laboratory Animal Technology Co. (Beijing).
Rag2−/− mice were purchased from HFK Bioscience Co.Table 2 Information of patients and corresponding patient-derived
Number Gender Age EGFR mutation
1 M 60 WT
2 M 69 WT
3 M 65 WT
4 M 67 WT
5 F 69 G719X/exon 19 del
6 M 62 WT
7 M 71 WT
8 M 62 WT
9 F 40 Exon 19 del
10 M 67 L858R
M male, F female, AC adenocarcinoma, LCC large cell carcinoma, SCC squamous cell(Beijing). We generated NOD-scid-IL2Rg−/− by TALEN-
mediated gene targeting in the NOD background and
named the new strain of immunodeficient mice NSI. The
absence of T, B, and NK cells in the PB, SP, and BM of
NSI mice was determined by Accuri™ C6 (BD Biosciences,
San Jose, CA, USA). All of the mice were bred and main-
tained in specific pathogen-free grade cages and provided
with autoclaved food and water.
Cell culture
RMA cells were obtained from Professor Pengtao Liu (Sanger
Institute, Cambridge, UK), and K562 cells were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). RMA, A549, and B16F10 cells were
maintained in RPMI-1640 medium (Gibco, New York,
NY, USA) with 10 % fetal bovine serum (FBS; Biochrom,
Australia). K562 cells were maintained in Iscove’s Modified
Dulbecco Medium (Thermo Scientific, MA, USA) with 10
% FBS. The 293T cells used for lentivirus packaging were
kindly provided by Professor Duanqing Pei (GIBH) and
maintained in Dulbecco’s Modified Eagle’s medium (Gibco,
New York, NY, USA) with 10 % FBS. All primary samples
were obtained with informed consent for research pur-
poses, and the procedures were approved by the Research
Ethics Board of the GIBH. All cells were cultured at 37 °C
in 5 % carbon dioxide and a normal level of oxygen.xenograft mouse models
Pathology Stage TNM stage Engrafted
AC IB T2N0M0 Yes
AC IIA T2N1M0 Yes
AC IA T2N0M1 Yes
LCC IA T2N1M0 Yes
AC IIB T2N1M0 No
AC IV T2N0M0 No
SCC IB T2N0M0 Yes
AC IIIA T2N2M0 No
AC IV T2N1M0 Yes
SCC IB T2N0M0 No
carcinoma
Fig. 6 Generation and characterization of the lung cancer xenograft model with NSI mice. Representative hematoxylin and eosin- and
immunohistochemistry-stained tissues of an adenocarcinoma (left) and corresponding early-generation xenografts (right); scale bar = 50 μm
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Twenty-four hours before the transfection, the HEK-
293T cells in logarithmic growth phase were trypsinized,
and the cell density was adjusted to 1.0 × 106 cells/mL
with complete culture medium. The cells were reseeded
into 15-cm cell culture dishes and cultured for 24 h before
transfection. When the cells were 90–95 % confluent on
the day of transfection, the recombinant viral vector en-
coding GFP and the two packaging plasmids psPAX2 and
pMD2.G were co-transfected into the HEK-293T cells
using Lipofectamine 2000 (Invitrogen, New York, NY,
USA) according to the manufacturer’s instructions. At48 h after transfection, the culture medium was collected
and centrifuged at 4000 × g at 4 °C for 10 min to remove
any cellular debris. The supernatant was filtered through a
0.45-μm filter and collected to transfect the RMA and
K562 cells. The RMA-GFP+ and K562-GFP+ cells were
sorted out using FACSAria™ II (Becton Dickinson, San
Jose, CA, USA) for culture.
Flow cytometry analysis
Cells were isolated from the PB, BM, and SP for flow cy-
tometric analyses. To analyze the human and mouse
cells, the cells were labeled with anti-hCD3-fluorescein
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hCD8a-peroxidase (PE), anti-hCD14-PE, anti-hCD33-
PE, anti-hCD71-PE, anti-hCD56-APC, anti-hIgM-eFluor
450, anti-hCD45-Percp Cy 5.5, anti-mCD4-PE, anti-mCD8-
peridinin chlorophyll (Percp) Cy 5.5, anti-mCD19-APC,
anti-mB220-Percp, anti-mCD3-APC, anti-mNKp46-PE,
anti-mCD71-PE, anti-m TER119-APC, anti-mCD11b-PE,
and anti-mGr-1-APC. All of the antibodies were obtained
from eBioscience (San Diego, CA, USA) unless specifically
stated. Flow cytometric analysis was performed using
Accuri C6 or FACSAria™ II. All of the data were analyzed
with FlowJo software (Tree Star, Inc., Ashland, OR, USA).Engraftments of leukemia and solid tumors
For a direct comparison of susceptibility to cancer cell en-
graftment, 1 × 104 (L), 1 × 105 (M), or 1 × 106 (H) of RMA-
GFP+, K562-GFP+, A549, or B16F10 cells suspended in
0.2 mL of phosphate buffer solution were injected into the
tail vein of five NSI, IL2Rg−/−, NOD-scid, scid, nude, and
WT mice. Similarly, 1 × 104 (L), 1 × 105 (M), or 1 × 106
(H) of A549 or B16F10 cells suspended in 0.2 mL of phos-
phate buffer solution were injected subcutaneously into
five NSI, IL2Rg−/−, NOD-scid, scid, nude, and WT mice.
The end points proposed were based on animal models in
widespread use [35]. The engraftment of leukemia was
measured by analyzing the GFP+ cells in the PB every
week or when the mice were moribund at a maximum of
90 days after grafting. Due to regulations of research ani-
mal welfare, we terminated the mice once the diameters
of their tumor reach 1.2 cm. 1B16F10 and A549 cells took
20 and 30 days, respectively, to develop into a 1.2-cm
tumor in NSI mice.Reconstitution of human hematopoiesis in NSI mice
The human cord blood was collected at the South China
Medical University (SCMU) Department of Gynecology
and Obstetrics with informed consent for research purposes
only, and this process was monitored by the Institutional
Review Boards of the SCMU. Human cord whole white
blood cells were isolated using Lymphoprep (Stemcell
Technologies, Canada) according to the manufacturer’s in-
structions. Human cord blood CD34+ cells were enriched
via magnetic cell sorting (Miltenyi, Bergisch Gladbach,
Germany). A total of 1 × 104 or 1 × 105 uncultured human
CD34+ cells were pooled together and injected intraven-
ously via the retro-orbital route into sub-lethally irradiated
(1.5 Gy) 8–10-week-old NSI mice. After 12 weeks, the
mice were killed, and the bone marrow from femurs was
analyzed by flow cytometry for the presence of human
CD45+ and blood lineage cells. In our engraftment assay,
the mice were considered to have been engrafted success-
fully when ≥0.1 % human CD45+ cells were detected in
the bone marrow 8 weeks after transplant.BLT mice
Human fetal thymus and liver tissues were obtained from
the SCMU. Human fetal thymus and liver fragments
measuring about 2 mm3 were implanted under the renal
capsule of sub-lethally irradiated NSI mice. The mice also
received CD34+ cells (5 × 105/mouse, intravenously) puri-
fied from the same donor on the day of human thymus/
liver transplantation. After 12 weeks, PBMCs from the re-
cipient mice were analyzed by flow cytometry for the pres-
ence of human CD45+ and blood lineage cells.Single-cell preparation
PBMCs were collected from B-ALL patients (SCMU
Department of Gynecology). To remove the red blood
cells, the cells were treated with 1 × RBC lysis buffer
(eBioscience) according to the manufacturer’s instructions.
To isolate a single cell from the B-ALL patients’ peripheral
blood, single-cell suspensions were prepared by standard
procedures. The single cell was then transplanted into
NSI mice.Enzyme-linked immunosorbent assay
The human Ig concentration in recipient serum was
measured by using a human Ig assay kit (ab100547,
Abcam, Cambridge, UK). To detect OVA-specific human
IgG antibodies, five recipient BLT mice were immunized
twice every 2 weeks with 100 μg of OVA (Sigma, St Louis,
MO, USA) that was emulsified in aluminum hydroxide
(Sigma). OVA was plated at a concentration of 10 μg/mL
in 96-microtiter wells at 4 °C overnight. After washing
and blocking with bovine serum albumin, the serum sam-
ples were incubated in the plate for 1 h. Antibodies bind-
ing OVA were then measured by a standard enzyme-
linked immunosorbent assay.Establishment of xenografts
Surgical tumor samples were obtained from the Sun Yat-Sen
University Cancer Center (Guangzhou, China), and cut
into 3–4-mm pieces and mixed then transplanted sub-
cutaneously within 30 min into three to six immunodefi-
cient NSI mice. The tumor-implanted mice were observed
daily for 90 days. Tumors were measured once a week by
caliper to determine the subcutaneous growth rate. At a
size of about 1 cm3, tumors were removed and passed on
to other NSI mice. Tumors were passed on no more than
10 times.Statistical analyses
Data were analyzed using GraphPad Prism 5 with the
Student’s t test. P values less than 0.05 were considered
statistically significant.
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Additional file 1: Figure S1. Establishment of K562-GFP and RMA-GFP
cell line. A. Flow chart of establishing K562-GFP and RMA-GFP cells that that
constitutively expressed green fluorescent protein (GFP). B. Representative
fluorescence-activated cell sorting plots show K562-GFP and RMA-GFP cells
before and after GFP+ enrichment.
Additional file 2: Figure S2. Experimental design for assessing the
capabilities of leukemic (top) or solid (bottom) grafts in immunodeficient
mice. Three groups of mice (five mice per group) were assayed; a high
number (1 × 106, H), medium number (1 × 105, M), and low number
(1 × 104, L) of grafts (K562-GFP, RMA-GFP, A549, and B16F10) were
injected into NSI, IL2Rg−/−, NOD-scid, scid, Rag2−/−, nude, and WT mice.
Additional file 3: Table S1. The final TEI scores of NSI, NOD-scid, scid,
nude, Rag2−/−, IL2Rg−/−, and WT mice measured by xenograft
experiments.
Additional file 4: Table S2. The final TEI score of NSI, NOD-scid, IL2Rg−/−,
Rag2−/−, scid, nude and WT mice measured by allograft experiments.
Additional file 5: Figure S3. Flow chart of the functional verification of
NSI mice by establishing a BLT model. Sub-lethally irradiated NSI mice were
transplanted with human fetal liver and thymus tissue from the same
human donors, and engrafted with autologous CD34+ hematopoietic
stem cells. BLT-NSI mice were tested with flow cytometry 12 weeks
after engraftment. At 12 weeks, BLT-NSI mice were immunized with
OVA twice and then the serum was analyzed for human IgG.
Additional file 6: Figure S4. Tumors dissected from NSCLC PDX mice
contained the bone marrow-derived cells of the hosts. Representative
plots of FACS analysis show dissociated cells from the tumors contained
both human cells (HLA+) and murine cells (MHC I+) that were further
subjected for analysis of murine Ly6g and CD11b expression.
Additional file 7: Figure S5. Generation and characterization of the
lung cancer xenograft model using dissociated tumour cells in NSI mice.
Primary tumors from NSCLC patients were digested and dissociated with
trypsin and were subsequently injected into NSI mice. Representative
hematoxylin and eosin-stained tissues of an adenocarcinoma (left) and
corresponding early-generation xenografts (right); scale bar = 50 μm.
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